Growing Awareness of PNH Drives Strong Demand for Soliris(R) in U.S. and
First Non-GAAP Profit; Sales Guidance Revised Upward
Pipeline Progress in Neurology and Cancer
First Quarter 2008 Financial Highlights:
- Soliris(R) (eculizumab) net product sales were $45.5 million in Q1 2008,
compared to net product sales of $33.9 million in Q4 2007.
- Q1 GAAP net loss was $4.2 million, or $0.11 net loss per share, compared
to a GAAP net loss of $12.3 million, or $0.33 net loss per share, in
- Q1 non-GAAP net income was $1.6 million, or $0.04 net income per share,
compared to a non-GAAP net loss of $8.5 million, or $0.23 net loss per
share, in Q4 2007.
CHESHIRE, Conn., April 30 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced financial results for the quarter ended March 31, 2008.
First Quarter 2008 Financial Results:
For the three months ended March 31, 2008, Alexion Pharmaceuticals,
Inc. ("Alexion" or the "Company") reported total revenues of $45.6 million
compared to total revenues of $6.3 million for the same period in 2007.
First quarter 2008 revenues were primarily from net product sales of
Soliris(R) (eculizumab): $45.5 million, compared to $1.0 million in the
first quarter of 2007 and $33.9 million in the fourth quarter of 2007.
Soliris, approved by the U.S. Food and Drug Administration (FDA) in March
2007 and the European Commission (EC) in June 2007, is the only drug
specifically indicated for the treatment of patients with paroxysmal
nocturnal hemoglobinuria ("PNH"), a rare, debilitating and life-threatening
|SOURCE Alexion Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved